No major financial impact from Abbott fenofibrate patent pact, Lupin says
This article was originally published in Scrip
Executive Summary
Lupin's recent licence agreement with Abbott Laboratories concerning various Abbott patents for the cholesterol drug, Antara (fenofibrate), will not have a significant financial impact on the Indian firm, its top brass has said.